Literature DB >> 21844115

Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients.

S Sazliyana1, M S Mohd Shahrir, C T Norella Kong, H J Tan, B B Hamidon, M T Azmi.   

Abstract

INTRODUCTION: Patients with systemic lupus erythematosus, particularly with lupus nephritis (LN), are at risk of premature cardiovascular (CV) disease.
OBJECTIVE: To determine the association between immunosuppressive medications, traditional CV risk factors and carotid intima media thickness (CIMT) among patients with LN.
METHODOLOGY: This was a cross-sectional study in which consecutive LN patients attending the Nephrology/SLE Clinic were evaluated for traditional CV risk factors. Detailed information on their treatment was obtained from their medical records. CIMT, an excellent marker of subclinical atherosclerosis, was measured by B Mode carotid ultrasound.
RESULTS: A total of 82 patients with LN with a mean age of 33.9 ± 9.8( )years were recruited. More than half had hypertension (n = 55, 67.1%) and dyslipidemia (n = 43, 52.4%) as traditional CV risks. Longer history and higher cumulative dose of corticosteroids were associated with hypertension, but use of intravenous methylprednisolone was associated with lower systolic and diastolic blood pressure and lower serum total cholesterol and triglyceride levels (p < 0.05 each). Hydroxychloroquine use was associated with lower total serum cholesterol and serum low-density lipoprotein levels (p < 0.05). Although the use of cyclosporine A (CyA) was associated with hypertension (p < 0.05), those who received a lower cumulative dose of CyA had thicker CIMT (r (s) = -0.33, p =0.01) and CyA use remained an independent predictor of CIMT during linear regression analysis. There were no associations between CIMT and cumulative dose and duration of steroids, hydroxychloroquine, azathioprine, mycophenolic acid and cyclophosphamide.
CONCLUSION: Aggressive treatment of severe LN and the use of CyA as a steroid-sparing agent may have protective effects against premature atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844115     DOI: 10.1177/0961203311411347

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

1.  The vascular phenotype of children with systemic lupus erythematosus.

Authors:  Catherine Quinlan; Jameela Kari; Clarissa Pilkington; John Deanfield; Rukshana Shroff; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-05-23       Impact factor: 3.714

Review 2.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

3.  Persistent hypertension in lupus nephritis and the associated risk factors.

Authors:  Syahrul Syazliana Shaharir; Ruslinda Mustafar; Rozita Mohd; Mohd Shahrir Mohd Said; Halim A Gafor
Journal:  Clin Rheumatol       Date:  2014-11-06       Impact factor: 2.980

Review 4.  Heart Failure in Chronic Infectious and Inflammatory Conditions: Mechanistic Insights from Clinical Heterogeneity.

Authors:  Nour Beydoun; Matthew J Feinstein
Journal:  Curr Heart Fail Rep       Date:  2022-07-15

Review 5.  Cardiovascular Implications of Immune Disorders in Women.

Authors:  Caitlin A Moran; Lauren F Collins; Nour Beydoun; Puja K Mehta; Yetunde Fatade; Ijeoma Isiadinso; Tené T Lewis; Brittany Weber; Jill Goldstein; Igho Ofotokun; Arshed Quyyumi; May Y Choi; Kehmia Titanji; Cecile D Lahiri
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 23.213

6.  Effect of cyclosporin A intervention on the immunological mechanisms of coronary heart disease and restenosis.

Authors:  Xuan Wang; Yue-Cheng Hu; Ru-Yan Zhang; Dong-Xia Jin; Yuan Jiang; He-Nan Zhang; Hong-Liang Cong
Journal:  Exp Ther Med       Date:  2016-10-04       Impact factor: 2.447

Review 7.  Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus.

Authors:  Alberto Floris; Matteo Piga; Arduino Aleksander Mangoni; Alessandra Bortoluzzi; Gian Luca Erre; Alberto Cauli
Journal:  Mediators Inflamm       Date:  2018-02-18       Impact factor: 4.711

8.  Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus.

Authors:  Deng-Ho Yang; Pui-Ying Leong; Sung-Kien Sia; Yu-Hsun Wang; James Cheng-Chung Wei
Journal:  J Clin Med       Date:  2019-06-05       Impact factor: 4.241

9.  Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications.

Authors:  May Y Choi; Daniel Li; Candace H Feldman; Kazuki Yoshida; Hongshu Guan; Seoyoung C Kim; Brendan M Everett; Karen H Costenbader
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

Review 10.  Risk factors in cardiovascular disease in systemic lupus erythematosus.

Authors:  Nailú Angélica Sinicato; Priscila Aparecida da Silva Cardoso; Simone Appenzeller
Journal:  Curr Cardiol Rev       Date:  2013-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.